Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23287990 | 0.91 | MEN1 (0.39) | CSF1RPPARGMEN1NPC1KMT2A | |
| SCHEMBL27240069 | 0.91 | CSF1R (0.40) | CSF1RNAMPTPPARG | |
| SCHEMBL27240059 | 0.89 | CSF1R (0.40) | CSF1RNAMPTBRAFMEN1NPC1 | |
| SCHEMBL23273761 | 0.87 | CSF1R (0.42) | CSF1R | |
| SCHEMBL27240078 | 0.87 | GRM5 (0.51) | CSF1R | |
| SCHEMBL23287969 | 0.86 | GRM5 (0.45) | CSF1RPPARGNPC1 | |
| SCHEMBL27240172 | 0.85 | GRM5 (0.39) | CSF1RNPC1 | |
| SCHEMBL27240046 | 0.84 | MEN1 (0.40) | CSF1RNAMPTPPARGMEN1KMT2A | |
| SCHEMBL23287985 | 0.83 | BTK (0.40) | NAMPTBRAFPPARG | |
| SCHEMBL29827331 | 0.82 | GRM5 (0.42) | CSF1RBRAFPPARGMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | CSF1R 4847/4885NAMPT 1110/4885BRAF 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.